Flagship · Bulletin

Macro rationale

NEUTRAL, unchanged. The live tape is calm — VIX 15.2 (-17% vs 200d SMA), HY OAS 2.67 below its 90d SMA, 2s10s +0.48 positively sloped — but three things keep me off risk-on: (1) QQQ +10.14% above its 200d fires the extension escalator, which mandates cash in the upper half of the band rather than the floor; (2) a 2.32% 10y real yield is a genuinely restrictive cost of capital with the Fed pinned at 3.50-3.75% and Warsh speaking at Jackson Hole tomorrow (8/28) with no forward guidance; (3) two-way Hormuz risk (Qatar de-escalation talks vs. Iran combat alert) plus Treasury/OFAC suspending five Iran general licenses — a regime-shift sanctions tightening that reads as a defense tailwind, an oil-supply tailwind, and a dual-use export-scrutiny overhang across compute simultaneously. Breadth is thin under the surface: only 63% of sectors above their 50d and equal-weight -3.06pp vs SPY over 1m, i.e. the index is being carried by the same compute/biology leadership (+7.5pp, +8.0pp rel SPY) that already dominates my book. That is the complacency gap the Aug-14 flagship named, and NVDA's +8.3% print today does not close it — it confirms the capex line while the labor market (-23k July NFP, -103k revisions) keeps cracking. Cash moves 21.91% -> 14.91%, back inside the NEUTRAL BASE band (5-15%) and above the enforced 13% working reserve, with a named cause: funding two named foundation opens. I am not citing the escalator to carry above-base cash this run because I no longer need to — the capital has a destination.

Thesis

Two tickets, both the same decision I committed on 8/25 and which did not reach the book: build the §3a foundation sleeve. Everything else is a verbatim hold at entry weight, delta 0. The trigger — NVDA Q2: $96.2B revenue +106% YoY, 75% GM, FY28 guide ~70% growth, and $279B of supply commitments (doubled). Read against my own unwind condition ("data-center revenue YoY <20% for two consecutive quarters"), that is confirmation, not a break — and the read-through to TSM (wafer demand), MU (the doubled supply commitment IS an HBM purchase line), AVGO (+143% AI revenue) and ANET is positive. The one real new fact is guided GM compression to 71-72% by Q4 FY28 on memory cost — worth naming, but a 71% gross margin is not a durability break, and it is the mirror image of MU's pricing power. So: hold NVDA at 3.61%, do NOT chase an +8.3% day. My own measured record says opus adds run -2.01% alpha at 30d and haiku high-flags run -3.99% at 7d; buying the print is the trade I have been punished for. Where the 7pp goes instead: CINF 3.5% (score 79, 8.4x P/E, 20% ROIC, 0.05x D/E, 65-year dividend-increase streak) and V 3.5% (score 60, 50.2% FCF margin, 64.7% ROIC, ~30x). Both dossier-backed (8/06, 21d old), both regime-indifferent ballast, both non-AI. AI-load stays 25.54%, compute 21.78%, no cap moves. Mid-cap sleeve, names actually considered and rejected: NTLA (flow 70, but pre-revenue $1.7B on a binary FDA decision — fails the durability bar, not the catalyst bar); SK ADR (HBM logic i

Reflection

NVDA's print confirmed the capex line rather than breaking it ($279B supply commitments, doubled). The only real work was finally landing the foundation build that did not execute on 8/25.

Second time I have committed the CINF/V opens and the second time I am writing them — the 8/25 book shows cash 14.91% and two foundation opens, the paper book shows cash 21.91% and neither. I need to stop assuming intent equals execution; the CCJ lesson (three failed paired trims, cured by changing ticket type) applies to opens too. Substantively: the honest tension this week is that NVDA's guided GM compression to 71-72% is the flip side of MU's pricing power. I own both. That is not a hedge, it is the same dollar counted twice — the memory cost NVDA eats is the memory margin MU earns. Worth

Positions (16)

• MUMicron Technologycompute

  hold4.59%87
  flow acceleratingconf

  Funder

  Only US-domiciled leading-edge DRAM/HBM franchise; 84.6% gross margin, FCF+, and after two decades of cycle abuse a three-player HBM oligopoly that is finally capacity-disciplined. Named flow: 16 Strategic Customer Agreements worth ~$100B of contracted volume with customer prepayments; NVDA's 8/27 disclosure of $279B supply commitments (doubled) is a named forward HBM purchase line; Micron $20B 20

  Unwind

  Erosion of the 14-16 SCA contract book or customer deposits being returned; HBM oversupply as new 2027 capacity lands; a named hyperscaler capex cut; gross margin sustained below ~60%; or a China/export action closing a material DRAM geography.

  Catalyst

  FQ4 earnings late September — HBM revenue mix and FY27 HBM4 share guidance against the 22-23% target.

  Scenarios · 12mo targets

  $1,100.00 base

  $1,400.00 bull — HBM4 share lands at 22-23% and DRAM stays sold out through 2027; the doubled NVDA supply commitment converts into multi-year priced volume.

  $650.00 bear — 2027 capacity additions break the oligopoly discipline, memory pricing rolls, and the SCA book gets renegotiated lower.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold6.93%86
  flow acceleratingconf

  Funder

  Effective foundry monopoly at <=3nm — every meaningful AI accelerator routes through it. >50% gross margin, prodigious FCF, famously disciplined capex, ~73% foundry and ~90% advanced-node share. Named flow: 2026 capex guided $60-64B; CoWoS booked out through end-2026 with NVDA taking ~60%; NVDA's $96.2B quarter and pulled-forward Vera Rubin ramp are TSMC wafer starts; Appaloosa/Thiel/Coatue added

  Unwind

  Gross margin sustained <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan-strait event Arizona capacity cannot offset; or 2nm yield slippage delaying the ramp.

  Catalyst

  Monthly revenue prints and the October Q3 call — 2nm contribution ramp and 2027 capex framing.

  Scenarios · 12mo targets

  $500.00 base

  $610.00 bull — 2nm ramps steeply on N2 pricing power while CoWoS expansion clears the queue; AI capex above $1T through 2027 routes through one supplier.

  $330.00 bear — Taiwan-strait escalation or a 2nm yield stumble that pushes the ramp out and compresses the leading-edge premium.

• NVDANVIDIAcompute

  hold4.29%74
  flow acceleratingconf

  Funder

  AI-accelerator franchise with the CUDA software moat — 74.9% gross margin, fortress balance sheet, developer lock-in no ASIC rival has replicated in a decade. Named flow: 8/27 Q2 print of $96.2B revenue +106% YoY with FY28 guidance implying ~70% growth, and $279B of disclosed supply commitments (doubled) — an audited forward purchase line, not a forecast. ~$725B of 2026 hyperscaler capex (MSFT/AMZ

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters; gross margin breaking below the guided 71-72% floor because memory cost cannot be passed through; hyperscaler in-sourcing plus AMD/ASIC wins pushing rival share toward the 25% TAM line; or a compute export-control action closing a material revenue geography.

  Catalyst

  Q3 FY27 print — Vera Rubin ramp revenue and whether gross margin holds above the 71-72% guided floor.

  Scenarios · 12mo targets

  $275.00 base

  $340.00 bull — Vera Rubin ships ahead of schedule and the doubled supply commitment converts to revenue; margin holds near 74% as memory cost is passed through.

  $165.00 bear — Memory cost compresses gross margin below 71% while ASIC in-sourcing at Google/Meta measurably slows accelerator unit growth.

• ASMLASML Holdingcompute

  hold3.52%62
  flow steadyconf

  Funder

  EUV / High-NA monopoly — the single most irreplaceable tool in advanced semis, no commercial-scale alternative at 2nm, a multi-year backlog, ~50% gross margin, and an installed-base service annuity that carries it through order troughs. Named flow: guided $36-40B 2026 revenue on 60 low-NA EUV units, a +25% unit step; TSMC's $60-64B and Micron's $20B capex are the order book; Norway GPFG holds, Coa

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; a Dutch/US export-control tightening removing a material share of the orderbook; or a credible non-EUV patterning path at 2nm. Score drift alone is not a trigger.

  Catalyst

  Q3 bookings in October — the book-to-bill reading against the 0.9 watch line I set.

  Scenarios · 12mo targets

  $2,000.00 base

  $2,450.00 bull — 2026 unit guidance is met or raised and High-NA moves into volume manufacturing, converting backlog into the guided $36-40B.

  $1,300.00 bear — Broadened Dutch/US export architecture removes China service and tool revenue while logic customers push out High-NA adoption.

• AVGOBroadcomcompute

  hold3.47%63
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~70% share) plus the VMware infrastructure-software lock-in — 69.5% gross margin, huge FCF, $7B+ annual buyback, a serial dividend grower, and Hock Tan's capital-allocation record. Named flow: Q2 AI semiconductor revenue +143% YoY to $10.8B with ~$16B guided for Q3; GOOG TPU multi-generation, META MTIA and Anthropic ASIC programs; Ark and Coatue adding on weakness.

  Unwind

  AI custom-chip revenue stalling below a ~$25B annual run-rate; full hyperscaler in-sourcing displacing the ASIC design franchise across multiple accounts (not one socket); or VMware renewal churn breaking the software annuity.

  Catalyst

  Q3 FY26 print in early September — whether AI revenue lands at the ~$16B guide and the bookings backlog holds.

  Scenarios · 12mo targets

  $430.00 base

  $530.00 bull — Q3 AI revenue clears $16B and a fourth named hyperscaler ASIC program is disclosed; VMware renewals sustain the software annuity.

  $265.00 bear — Marvell/in-house designs take a second and third socket while NVDA's full-rack platform absorbs the networking attach AVGO counts on.

• ANETArista Networkscompute

  hold3.09%65
  flow steadyconf

  Funder

  Durable hyperscaler-networking franchise and a consistent share-gainer since 2004 — 62.9% gross margin, 45% GAAP operating margin, zero debt, $4.3B FCF, and the single-image EOS software moat that makes rip-and-replace expensive. Named flow: record $3B quarter with eight consecutive quarters of sequential growth; Microsoft and Meta are the named funding customers; the Arista 2.0 platform extends t

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; Spectrum-X or whitebox displacing EOS in a NAMED hyperscaler footprint; or gross margin breaking below ~60%.

  Catalyst

  Q3 print — AI back-end revenue disclosure and any named hyperscaler footprint loss to Spectrum-X.

  Scenarios · 12mo targets

  $235.00 base

  $290.00 bull — Arista 2.0 converts AI back-end Ethernet share at scale and a third named hyperscaler joins Microsoft and Meta above 10% of revenue.

  $145.00 bear — NVDA networking (now $14.8B, 21.5% share) takes a named hyperscaler footprint and forces price concessions on EOS renewals.

• GEVGE Vernovaenergy

  hold5.39%61
  flow acceleratingconf

  Funder

  Gas-turbine and grid franchise with genuine pricing power — heavy-duty turbines effectively sold out through 2030, 10-20% price realization on new orders, an installed-base service annuity, and post-spin balance-sheet discipline. Named flow: $176B backlog +37% YoY with data-center power equipment revenue doubling to $5B in H1 2026; Morgan Stanley's 38GW power-gap estimate; Norway GPFG added post-s

  Unwind

  Gas-turbine backlog cancellation or a named hyperscaler power-capex cut; wind-segment losses widening enough to consume gas-segment profit; or the order book ceasing to price at 10-20% realization.

  Catalyst

  Q3 order-book disclosure — backlog growth and gas-segment margin against the sold-out-through-2030 claim.

  Scenarios · 12mo targets

  $1,120.00 base

  $1,350.00 bull — Backlog crosses $200B with price realization holding and the wind drag finally turns neutral; grid/T&D remains the binding AI constraint.

  $700.00 bear — A hyperscaler power-capex pause cancels turbine slots while wind losses keep consuming gas-segment profit.

• SCCOSouthern Copperenergy

  hold9.10%67
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost major copper producer with the industry's largest reserve base, 67.6% gross margin, FCF positive with a large dividend, and Grupo Mexico control enforcing capital discipline through the cycle. Named flow: structural copper deficit with AI data centers consuming ~50k tonnes per facility; full-year guidance RAISED to 917k tonnes despite grade drag; the 1.6M-t

  Unwind

  Copper price collapse breaking the deficit thesis; Tia Maria / Los Chancas permitting reversal; a dividend cut signalling balance-sheet stress; or a Peruvian/Mexican fiscal or nationalization shock.

  Catalyst

  H2 production report — whether Peruvian ore grades stabilize against the -3.8% H1 decline.

  Scenarios · 12mo targets

  $245.00 base

  $300.00 bull — Peru grades stabilize, the deficit widens on AI/electrification demand, and Tia Maria permitting advances toward the 1.6M-tonne path.

  $165.00 bear — Grade decline persists past 2026 while a China demand air-pocket collapses copper, compressing the dividend.

• NEMNewmont Corporationenergy

  hold6.00%83
  flow acceleratingconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer with tier-1 long-life assets, strong post-Newcrest FCF and dividend, and visibly improving cost discipline after the divestiture program. Named flow: central-bank gold accumulation plus Treasury's doubling of long-dated bond buybacks (the 8/19 +7.9% move) compressing the long end; a 2.32% real yield with the Fed pinned at 3.50-3.75% and unable t

  Unwind

  Cost overruns or mine disappointments breaking FCF and the dividend; durable disinflation plus a real-rate surge removing the stagflation-hedge rationale; or the $1.95B Barrick settlement payment forcing capital-return cuts.

  Catalyst

  Q3 AISC print and the cash impact of the $1.95B Barrick settlement on the dividend/buyback pace.

  Scenarios · 12mo targets

  $155.00 base

  $195.00 bull — Real yields fall on a labor-driven Fed capitulation while central-bank buying persists; AISC discipline holds and FCF funds a larger return.

  $100.00 bear — Core CPI breaks below 2.2%, real yields surge, gold de-rates, and the $1.95B settlement plus cost overruns squeeze the dividend.

• KTOSKratos Defensedefense

  hold11.41%64
  flow steadyconf

  Funder

  Scarce non-prime supplier of attritable airframes (XQ-58A Valkyrie), hypersonics and turbine engines, with a decade of embedded program positions the primes cannot easily displace and vertical propulsion capability few competitors own. Named flow: DoD MACH-TB 2.0 $1.45B IDIQ; Project Helios $68.3M; USMC Valkyrie mods; hypersonic revenue doubling toward $400M with a $700M 2027 path and a $50M paylo

  Unwind

  Backlog or contract cancellations; margin failing to inflect through the drone ramp with FCF staying negative; a DoD unmanned-systems funding cut; or an FY2027 appropriation that de-funds the attritable-airframe line.

  Catalyst

  FY2027 appropriations / CR resolution (current CR to Dec 4) and the next quarter's margin print on the drone ramp.

  Scenarios · 12mo targets

  $65.00 base

  $85.00 bull — Hypersonic revenue doubles to $400M on schedule, drone-segment margin inflects positive, and the FY27 DAWG line converts to firm orders.

  $36.00 bear — CR drags new starts past mid-2027, FCF stays negative through the ramp, and a 95x forward multiple de-rates hard.

• HEIHEICOdefense

  hold10.23%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder and a textbook 20-30 year franchise — the Mendelson family has owned and run it since 1957, compounding FCF above 20% through disciplined tuck-in serial acquisition and PMA parts that are structurally cheaper than OEM. Named flow: Q2 record net income +49% YoY on sales +25% (FSG $929M vs $864M cons., ETG $460M vs $396M, ETG operating income +56%); NDAA mandatory

  Unwind

  Organic growth decelerating below 6% WITH margin compression; a value-destroying large acquisition breaking the tuck-in discipline; or forward P/E above 50x AT decelerating growth (the multiple alone is not the trigger — growth is +25% and accelerating).

  Catalyst

  FQ3 print — organic growth rate and whether ETG margin expansion persists at the 54x multiple.

  Scenarios · 12mo targets

  $390.00 base

  $470.00 bull — Aftermarket cycle plus ETG defense electronics sustain 20%+ organic growth; the Mendelsons deploy $1B+/yr of tuck-ins at accretive prices.

  $250.00 bear — One guidance cut simultaneously trips the >50x multiple and the <6% growth screen; RSI 35 and -2.6% today say the de-rating has started.

• LLYEli Lillybiology

  hold5.67%73
  flow steadyconf

  Funder

  Premier pharma compounder — the tirzepatide franchise on 85.8% gross margin plus a manufacturing moat from the $27B capacity build rivals cannot replicate quickly, run by a team with a genuine record of reinvesting into durable franchises. Named flow: FY2026 revenue guidance RAISED to $85-87B; Mounjaro +91% YoY to $9.9B, Zepbound $4.9B; Foundayo won the UK's first oral GLP-1 approval; H1 oncology

  Unwind

  Tirzepatide US script share falling >5pts to Novo over two quarters; retatrutide Phase 3 disappointing on safety or durability; or IRA/MFP negotiation reaching the tirzepatide molecule with a material price cut.

  Catalyst

  Retatrutide Phase 3 readout and the Q3 print — US GLP-1 script share vs. Novo's CagriSema launch.

  Scenarios · 12mo targets

  $1,400.00 base

  $1,700.00 bull — Retatrutide Ph3 confirms 28.7% weight loss with clean safety and orforglipron scales the oral TAM; guidance goes above $87B.

  $900.00 bear — CagriSema takes >5pts of US share and MFP/IRA negotiation reaches tirzepatide, compressing both volume and price.

• VRTXVertex Pharmaceuticalsbiology

  hold4.71%81
  flow steadyconf

  Funder

  Durable biology compounder: the cystic-fibrosis monopoly (Trikafta/Alyftrek) is a self-funding cash engine on 85.3% gross margin with a fortress net-cash balance sheet — profitable, so it is insulated from the 2.32% real-yield vise that punishes cash-burn biotech. Named flow: Sionna's CF trial failure removed the only credible near-term challenger, extending exclusivity into the late 2030s and wid

  Unwind

  The CF franchise eroding faster than non-CF revenue can replace it; the Crinetics integration destroying value; or forward P/E pushing toward the 30x invalidation on decelerating growth.

  Catalyst

  Journavx launch metrics and Casgevy reimbursement uptake in the Q3 print.

  Scenarios · 12mo targets

  $640.00 base

  $780.00 bull — Alyftrek conversion plus the 95%-of-patients label extends CF revenue growth while Journavx becomes a real second franchise.

  $430.00 bear — Journavx launch stalls, Casgevy uptake stays negligible, and CF growth flattens with nothing to replace it at a 25x+ multiple.

• ARGXargenxbiology

  hold4.63%69
  flow acceleratingconf

  Funder

  argenx — the Vyvgart/Vyvgart Hytrulo (efgartigimod) FcRn autoimmune franchise: first-mover platform with a decade of indication runway, commercial-stage, high-margin and net cash, so it does not depend on capital markets. Named flow: FDA expanded gMG approval to all serotypes (~18% TAM expansion); Sanofi's riliprubart CIDP Phase 3 failure removed the nearest competitor; the completed Forte Bioscie

  Unwind

  Vyvgart revenue growth stalling; a pipeline indication failure in myositis or Sjogren's; a competitor FcRn entrant taking measurable share; or the Forte deal turning into a serial-dilution habit rather than a one-off.

  Catalyst

  Myositis and Sjogren's efgartigimod readouts, and Q3 Vyvgart Hytrulo prefilled-syringe conversion rate.

  Scenarios · 12mo targets

  $1,250.00 base

  $1,550.00 bull — Myositis and Sjogren's both read out positive, extending the FcRn label runway while Hytrulo conversion lifts gross margin.

  $780.00 bear — An indication failure plus a competitor FcRn launch stalls Vyvgart growth; RSI 72 leaves no cushion for disappointment.

• NVSNovartis AGbiology

  hold3.00%51
  flow steadyconf

  Funder

  Top-5 global pharma with genuinely diversified in-market cash flow — Kisqali, Scemblix, Leqvio, Fabhalta, Cosentyx — on ~40% core operating margin and strong FCF, run by a management team whose allocation record is subtraction (Sandoz, Alcon) rather than empire-building. Named flow: the Pluvicto radioligand capacity build at Denton/Indianapolis; the Ionis/Novartis HORIZON pelacarsen Lp(a) readout

  Unwind

  Scale-in to ~5% requires two consecutive quarters of >=6% cc growth with core margin >=40%. Kill criteria: core margin below 35%, group revenue turning negative on the Entresto LOE, or a large value-destroying acquisition. Score 51 was known and underwritten at entry four days ago — the score is not the kill criterion.

  Catalyst

  HORIZON pelacarsen Lp(a) Phase 3 readout in H2 2026 — the largest single pipeline event in the name.

  Scenarios · 12mo targets

  $178.00 base

  $205.00 bull — Pelacarsen HORIZON hits on the Lp(a) hypothesis, opening a multi-billion CV franchise while Kisqali/Scemblix absorb the Entresto LOE.

  $130.00 bear — HORIZON misses and the Entresto LOE turns group revenue negative before the newer brands scale; core margin slips below 35%.

• BEAMBeam Therapeutics Inc. Common Stockbiology

  hold1.50%43
  flow steadyconf

  Funder

  Origin platform for base editing (David Liu science, Broad-licensed): single-base correction without double-strand breaks — the most differentiated editing chemistry in the field — with ~$1.21B cash funding BEAM-302 in AATD into mid-2029, so it does not need the capital markets during the rate vise. Named flow: BEAM-302 Phase 1/2 showed durable efficacy AND clean safety across 29 patients; ARK Inv

  Unwind

  Kill immediately on any grade 3+ hepatotoxicity or off-target signal in BEAM-302/301 (the Verve-101 precedent), on a discounted equity raise before the AATD pivotal, or on the cash runway shortening inside two years. A sub-60 score was explicitly underwritten at entry and is not itself a kill.

  Catalyst

  BEAM-302 pivotal-design alignment with FDA and the CTX/ESCAPE in-vivo Phase 1 initiations.

  Scenarios · 12mo targets

  $40.00 base

  $65.00 bull — BEAM-302 pivotal design is agreed under the platform guidance and a large-pharma partnership validates the chemistry with non-dilutive capital.

  $14.00 bear — A grade 3+ liver signal or off-target finding in BEAM-302 forces a hold, and the runway shortens into a discounted raise.

Warnings

• §2 cap applied: KTOS
• hedge_floor: only 2/3 tail-risk names held (floor escalated: AI-load 31.3% > 30%) — open a gold/oil/diversified-commodity hedge (§5.3); uranium & power-gen do not count
• buy guard dropped 2 open(s): CINF, V (§3/§4/§6.3)

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —
2. Turn 2ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.